CA-SOLIDIGM
Today, Solidigm, a leading provider of innovative NAND flash memory solutions, announced the launch of the SolidigmTM D7-PS1010 and D7-PS1030 data center solid-state drives (SSDs). As the fastest PCIe 5.0 SSDs1 shipping in volume today, these drives are well suited for the IO intensity found in modern mainstream, mixed, and write-centric workloads.
“The Solidigm D7-PS1010 and D7-PS1030 SSDs were meticulously engineered to meet the increasingly demanding IO requirements across a range of workloads such as general-purpose servers, OLTP, server-based storage, decision support systems and AI/ML,” said Greg Matson, Senior Vice President of Strategic Planning and Marketing at Solidigm. “In a world where every watt counts, these drives are PCIe 5.0 done right, not only delivering industry-leading four-corner performance,2 but also up to 70% better energy efficiency compared to similar drives by other manufacturers.3”
Available in E3.S and U.2 form factors, the newest Solidigm SSDs come in a range of capacities and endurance options and are a strong extension to the company’s portfolio of best-in-industry storage for AI.
D7-PS1010
A standard endurance (SE) drive, the Solidigm D7-PS1010 is available in 1.92TB, 3.84TB, 7.68TB, and 15.36TB capacities. Over a 5-year period, the SE models provide 1.0 drive writes per day (DWPD) and boast substantial maximum lifetime program/erase cycles, with 28 petabytes written (PBW) for the 15.36TB variant. In server-based storage solutions, the D7-PS1010 can accelerate sequential write throughput up to 37 percent faster than drives with similar specifications.4 Offering a balance of performance and capacity, this drive is ideal for a wide range of mainstream applications.
D7-PS1030
A mid-endurance (ME) drive, the Solidigm D7-PS1030 is available in 1.6TB, 3.2TB, 6.4TB, and 12.8TB capacities and offers an impressive 70 PBW for the 12.8TB variant. When placed in an all-flash performance tier for AI workloads, the D7-PS1030 helps overcome hard disk drive (HDD) performance, endurance, and reliability limitations. With write performance more than double that of the previous generation Solidigm drive,5 the D7-PS1030 is particularly suited for operations requiring write-intensive usages such as caching and checkpointing.
The new drives are built to excel at every stage of the AI data pipeline and deliver up to 50 percent higher throughput in certain pipeline phases6 compared to similar drives in their class. These SSDs can be deployed as GPU direct attach drives in GPU servers or as part of a high-performance all-flash tier supporting lower-performing HDDs in network attach storage configurations.
“As AI workloads continue to surge, storage performance becomes critical,” said Ace Stryker, Director of Market Development at Solidigm. “The Solidigm D7-PS1010 and D7-PS1030 are a game-changer for AI-driven enterprises, capable of outperforming competitors at critical stages of the AI pipeline.”
With this launch, Solidigm continues its commitment to delivering industry-leading quality and reliability. By employing methodologies like testing to zero tolerance for data errors,7 built-in redundancies, enhanced power loss management, and engineering for performance consistency over the life of the drive,8 these SSDs far surpass required industry specifications and common practices. Combined with new OCP-compliant thermal management capabilities, and new security capabilities such as secure boot and data at rest protection and attestation, the D7-PS1010 and D7-PS1030 drives are designed to be deployed with utmost confidence in cloud and enterprise usages.
For more information on how Solidigm D7-PS1010 and Solidigm D7-PS1030 drives can help you power your workloads, visit our website.
About Solidigm
Solidigm is a leading global provider of innovative NAND flash memory solutions. Solidigm technology unlocks data’s unlimited potential for customers, enabling them to fuel human advancement. Originating from the sale of Intel’s NAND and SSD business, Solidigm became a standalone U.S. subsidiary of semiconductor leader SK hynix in December 2021. Headquartered in Rancho Cordova, California, Solidigm is powered by the inventiveness of team members in 13 locations around the world. For more information, please visit solidigm.com and follow us on Twitter and on LinkedIn. “Solidigm” is a trademark of SK hynix NAND Product Solutions Corp. (d/b/a Solidigm).
______________________
1 Comparing product specifications and measured real-life workload performance across widely shipping PCIe 5.0 data center SSDs at the industry’s highest volume capacity point of 3.84TB (using Solidigm 2023 and 2024 shipments as industry representative data).
2 Four-corner comparison data is based on publicly available information from Samsung, Kioxia, and Micron.
3 Comparing 7.68TB, Samsung PM1743 and Solidigm D7-PS1010. Power is measured using Quarch Technology. Solidigm D7-PS1010 (128KB SW QD128 IOPS/Watt 3,874), Samsung PM1743 (128KB SW QD128 IOPS/Watt 2,272).
4 Workload IO characteristics based on research of publicly available materials conducted by Solidigm. Comparing SolidigmTM D7-PS1010 3.84TB (128KB Seq Write QD128 8.2 MB/s) vs Samsung PM1743 3.84TB (128KB Seq Write QD128 6.0 MB/s).
5 As compared to previous generation Solidigm™ D7-P5520 and D7-P5620.
6 Workload IO characteristics based on research of publicly available materials conducted by Solidigm. SolidigmTM D7-PS1010 7.68TB (32KB SW QD32 9.03GB/s 113us) vs Samsung PM1743 7.68TB (32K SW QD32 6.03GB/s 170us).
7 Solidigm drives are tested to 1E-18 under full range of conditions and cycle counts throughout the life of the drive which is 100X higher than 1E-16 specified in JEDEC – Solid State Drive Requirements and Endurance Test Method (JESD218). https://www.jedec.org/standards-documents/focus/flash/solid-state-drives.
8 Refer to SolidigmTM D7-PS1010 product specifications for IOPS consistency. Solidigm expects up to 5% variation in throughput between drive-to-drive runs. IOPS variability measured after adjusting SSD cycle limit to simulate end of life behavior. Results are estimated or simulated. Actual results may vary.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806563458/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom